Literature DB >> 2021315

Spurious serologic test results in patients receiving infusions of intravenous immune gammaglobulin.

B Lichtiger1, K Rogge.   

Abstract

Intravenous immune gammaglobulin (IVIgG) has a definite role in the modern armamentarium of therapies for immunocompromised patients. Intravenous IgG is manufactured from the plasma of a large number of donors and contains antibodies against numerous infectious agents. Patients who receive infusions of IVIgG may test false-positive for a variety of viral, bacterial, and other infectious diseases when serologic determinations are performed on their blood samples. It is important that laboratories performing serologic testing be aware that patients have been infused with IVIgG, so that spurious laboratory results can be identified. Serologic testing on implicated lots of IVIgG and on the patient's pretreatment sample may aid in correctly identifying a spurious serologic result due to therapy with IVIgG.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2021315

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN： 0003-9985            Impact factor:   5.534


  10 in total

1.  Intravenous immunoglobulin therapy: confounding effects on serological screening for toxoplasmosis during pregnancy.

Authors:  H Pelloux; H Fricker-Hidalgo; G Brochier; A Goullier-Fleuret; P Ambroise-Thomas
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

2.  Positive hepatitis serologies with treatment for Kawasaki syndrome.

Authors:  S M Borowitz
Journal:  Arch Dis Child       Date:  1993-01       Impact factor: 3.791

3.  Positive serological tests for syphilis and administration of intravenous immunoglobulin.

Authors:  S A Constable; C M Parry; T P Enevoldson; M Bradley
Journal:  Sex Transm Infect       Date:  2007-02       Impact factor: 3.519

4.  Actionable diagnosis of neuroleptospirosis by next-generation sequencing.

Authors:  Michael R Wilson; Samia N Naccache; Erik Samayoa; Mark Biagtan; Hiba Bashir; Guixia Yu; Shahriar M Salamat; Sneha Somasekar; Scot Federman; Steve Miller; Robert Sokolic; Elizabeth Garabedian; Fabio Candotti; Rebecca H Buckley; Kurt D Reed; Teresa L Meyer; Christine M Seroogy; Renee Galloway; Sheryl L Henderson; James E Gern; Joseph L DeRisi; Charles Y Chiu
Journal:  N Engl J Med       Date:  2014-06-04       Impact factor: 91.245

Review 5.  Adverse effects of intravenous immunoglobulin.

Authors:  S A Misbah; H M Chapel
Journal:  Drug Saf       Date:  1993-10       Impact factor: 5.606

Review 6.  ASO titer or not? When to use streptococcal serology: a guide for clinicians.

Authors:  T Parks; P R Smeesters; N Curtis; A C Steer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-01-06       Impact factor: 3.267

7.  IV immunoglobulin confounds JC virus antibody serostatus determination.

Authors:  Ilya Kister; Geoffrey Kuesters; Eric Chamot; Mirza Omari; Kim Dontas; Mary Yarussi; Meena Subramanyam; Joseph Herbert
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2014-09-18

8.  Detection of Antibodies Against Human Leukocyte Antigen Class II in the Sera of Patients Receiving Intravenous Immunoglobulin.

Authors:  Hiroyuki Takamatsu; Shinya Yamada; Noriaki Tsuji; Noriharu Nakagawa; Erika Matsuura; Atsuo Kasada; Keijiro Sato; Kohei Hosokawa; Noriko Iwaki; Masahisa Arahata; Hidenori Tanaka; Shinji Nakao
Journal:  Transplant Direct       Date:  2021-05-18

Review 9.  Challenges in Detection of Serum Oncoprotein: Relevance to Breast Cancer Diagnostics.

Authors:  Justin Lengfeld; Hongtao Zhang; Steven Stoesz; Ramachandran Murali; Franklin Pass; Mark I Greene; Peeyush N Goel; Payal Grover
Journal:  Breast Cancer (Dove Med Press)       Date:  2021-10-14

10.  Case report: passive transfer of hepatitis B antibodies from intravenous immunoglobulin.

Authors:  Simon Parker; Eliza Gil; Patricia Hewitt; Katherine Ward; Yasmin Reyal; Sasha Wilson; Jessica Manson
Journal:  BMC Infect Dis       Date:  2014-02-22       Impact factor: 3.090
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.